MOLECULAR DOCKING STUDIES OF MAGE INHIBITORS IN THE TREATMENT OF LUNG CANCER
Abstract
The insilico methods for drug discovery are becoming increasingly powerful and useful. That in combination with increasing computer processor power. Lung cancer is the leading cause of cancer associated deaths Worldwide and has one of the poorest prognoses among all cancer types. A variety of melanoma antigen A (MAGE-A) genes are commonly detected in non-small cell lung cancers. Their biological function is not well characterized but may involve the regulation of apoptosis and cell cycle progression. In this study  ligand-based drug design were employed to design novel MAGE inhibitors from  Naringi crenulata found in  Asia. The MAGE structure model was built in homology modelling based on known receptors of the same family.  A phytochemicals of Naringi crenulata are analysed and optimized with the Arguslab to investigate the interactions between the target compounds and the amino acid residues of the Mage protein .All the compound have shown binding pose  between  from – 6.54 to -15.34.out of five compound 1,2-benzenedicarboxylic acid show best ligand energy -8.15Kcal/mol with  3 hydrogen  bond of distance is 2.1,3.0 and 2.3            Â
Â
 Key Words: Lung Cancer, Mage Protein, Docking, Modelling, Naringi Crenulata,Argus lab
Downloads
References
Kasahara S and Hemini S. Medicinal Herb Index in Indonesia, Bogor, Indonesia, P.T. Eisai Indonesia. 1998;1 2
. AmitArora and Eric M. Scholar, Role of Tyrosine Kinase
Inhibitors in Cancer Therapy. J Pharmacol Exp Ther 2005; 315: 971-979.
US Department of Health, and Human Services (USDHHS). Reducing the health consequences of smoking: 25 years of progress; a report of the Surgeon General. 1989 US Government Printing Office. Washington, DC:
Churg, A Lung cancer cell type and occupational exposure. Samet, JM eds. Epidemiology of lung cancer 1994, 413-436 Marcel Dekker. New York, NY
Fischer C, Gudat F, Stulz P, Noppen C, Schaefer C, Zajac P, Trutmann M, Kocher T, Zuber M, Harder F et al. 1997
High expression of MAGE-3 protein in squamous-cell lung carcinoma. International Journal of Cancer 71 1119–1121.
Jang SJ, Soria JC, Wang L, et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 2001; 61: 7959–63
Sakata M. Expression of MAGE gene family in lung cancers. Kurume Med J1996; 43: 55–61.
Yoshimatsu T, Yoshino I, Ohgami A, et al. Expression of the melanoma antigen-encoding gene in human lung cancer. J Surg Oncol 1998; 67: 126–9.
Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 2002; 67: 705–12.
Ohman Forslund K, Nordqvist K. The melanoma antigen genes-any clues to their functions in normal tissues? Exp Cell Res 2001; 265: 185–94.
van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–7.
Tramontano,A., Leplae,R. and Morea,V, Analysis and assessment of comparative modeling predictions in CASP4. Proteins, 45 (Suppl. 5),22–38, (2001).
Marti-Renom,M.A., Stuart,A.C., Fiser,A., Sanchez,R., Melo,F. and Sali,A, Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct., 29, 291–325,(2000).
Binkowski TA, S. Naghibzadeh and J. Liang, CASTp: Computed Atlas of Surface Topography of proteins. NucleicAcids Res. 31:3352-5, (2003).
Warren G.L, C.W Andrews, A.M Capelli, B. Clarke, J. LaLonde, M.H Lambert, M. Lindvall, N. Nevins, S.F Semus, S. Senger, G. Tedesco, I.D Wall, J.M Woolven, C.E Peishoff and M.S Head,Acritical assessment of docking programs and scoring functions. J Med Chem. 49(20): 5912-31, (2006).
Christopher A. Lipinski, Franco Lombardo, Beryl Dominy and Paul J. Feeney, 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23(1-3):3-25.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.